Health Canada Approves PRRSV-Resistant Pigs for Food Use

Health Canada announced on Friday that food derived from pigs genetically modified to resist a specific porcine virus is just as safe and nutritious as conventional pork available in stores.

The federal authorities declared that pigs engineered to be resistant to porcine reproductive and respiratory syndrome viruses (PRRSV), which are known to be highly damaging to farmed pigs, are safe for use in food products and animal feed.

Genus PLC, a company based in the U.K. that provides top-tier genetics to farmers, along with PIC Canada, Ltd., located in Winnipeg, sought approval from Health Canada and the Canadian Food Inspection Agency to market these gene-edited products for food and feed purposes.

According to Health Canada, enhancing pigs’ resistance to PRRSV will help herds avoid diseases caused by these viruses, decrease the need for antibiotics, and promote better animal welfare, all while contributing to a more stable, cost-effective, and sustainable food supply.

Genus PLC’s pigs resistant to PRRSV have already been authorized for food use in the United States, Brazil, Colombia, and the Dominican Republic. The company plans to wait for regulatory approvals in other significant markets before selling these pigs, Health Canada noted.

“Since Health Canada identified no health and safety issues, there is no requirement for special labeling on products from these PRRSV-resistant pigs,” the agency stated.

Over 25 years ago, researchers at Memorial University in Newfoundland created a salmon that became the first transgenic food animal authorized for sale in Canada. Marketed as AquAdvantage Salmon, its DNA was sourced from Pacific salmon and the eel-like ocean pout.

At that time, the Council of Canadians expressed concerns regarding the volume of water utilized, waste produced, and the transportation of eggs between facilities.

In contrast to the genetically modified salmon, the PRRSV-resistant pigs were developed using CRISPR gene-editing technology, which allows for precise genetic modifications without incorporating genetic material from other species, according to scientists.

“This marks the first gene-edited animal to receive approval for commercial sale in Canada,” stated Gwendolyn Blue, a professor in the geography department at the University of Calgary, who investigates the political and ethical dimensions of gene editing.

While Blue acknowledges the potential benefits of PRRSV-resistant pigs, she also highlights ethical, moral, cultural, and political concerns related to the approval process, such as the criteria used for safety evaluations and the updates to biotechnology regulations in Canada.

“One of the issues raised in Canada is the lack of mandatory labeling,” she remarked. “This aspect is currently being reviewed.”

To create pigs that are resistant to PRRS, Genus PLC eliminated a segment of a specific gene that the PRRS virus relies on to infect pigs.

“Health Canada and Genus PLC are dedicated to maintaining the highest level of transparency and will inform the public when these pigs enter the Canadian market,” a Health Canada representative stated on Wednesday.

CRISPR technology has also found experimental applications in medicine. In 2025, U.S. doctors utilized CRISPR for personalized gene therapy for a baby suffering from a rare and severe genetic disorder.

In 2023, the United Kingdom’s medicines regulator granted authorization for the first gene therapy treatment globally for sickle cell disease and thalassemia, conditions resulting from genetic errors in hemoglobin-carrying genes.